Megan E V Caram1, Samuel R Kaufman2, Parth K Modi2, Lindsey Herrel2, Mary Oerline2, Ryan Ross3, Ted A Skolarus4, Brent K Hollenbeck2, Vahakn Shahinian5. 1. Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI; VA Health Services Research & Development, Center for Clinical Management and Research, VA Ann Arbor Healthcare System, Ann Arbor, MI. Electronic address: mveresh@med.umich.edu. 2. Department of Urology, University of Michigan Medical School, Ann Arbor, MI. 3. Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI. 4. VA Health Services Research & Development, Center for Clinical Management and Research, VA Ann Arbor Healthcare System, Ann Arbor, MI; Department of Urology, University of Michigan Medical School, Ann Arbor, MI. 5. Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI; Department of Urology, University of Michigan Medical School, Ann Arbor, MI.
Abstract
OBJECTIVE: To investigate the adoption of abiraterone and enzalutamide by urologists. Abiraterone and enzalutamide are oral therapies approved for the treatment of metastatic castration-resistant prostate cancer, a disease most commonly treated by medical oncologists. METHODS: Using the Medicare Part D Public Use Files from 2013 to 2016, we identified total abiraterone and enzalutamide prescriptions 2013-2016 and urologists who prescribed moderate to high volumes of these drugs. We then characterized the urologist practices of those urologists according to practice context (eg, single-specialty group) using data from the Centers for Medicare and Medicaid Services, and the geographic distribution of those providers. RESULTS: We found abiraterone prescriptions increased from 71,423 in 2013 to a peak of 100,371 in 2015 and enzalutamide prescriptions continued to increase from 29,572 in 2013 to 100,980 in 2016. Prescriptions by urologists increased between 2013 and 2016 while prescriptions by other specialties plateaued. The number of moderate-high prescribing urologists increased from 98 (abiraterone) and 22 (enzalutamide) in 2013, to 301 (abiraterone) and 671 (enzalutamide) by 2016 with 1063 unique urologists prescribing moderate-high volumes of either drug between 2013 and 2016. Among urologists who prescribe androgen deprivation therapy, 5% were moderate-high prescribers of abiraterone and 12% of enzalutamide in 2016. The majority of moderate-high prescribing urologists were in single-specialty groups (70%). CONCLUSION: Urologists are increasingly prescribing oral therapies for metastatic castration-resistant prostate cancer. Understanding the distribution of urologists specializing in castration-resistant prostate cancer therapeutics will help guide future interventions to optimize the care for this important patient population.
OBJECTIVE: To investigate the adoption of abiraterone and enzalutamide by urologists. Abiraterone and enzalutamide are oral therapies approved for the treatment of metastatic castration-resistant prostate cancer, a disease most commonly treated by medical oncologists. METHODS: Using the Medicare Part D Public Use Files from 2013 to 2016, we identified total abiraterone and enzalutamide prescriptions 2013-2016 and urologists who prescribed moderate to high volumes of these drugs. We then characterized the urologist practices of those urologists according to practice context (eg, single-specialty group) using data from the Centers for Medicare and Medicaid Services, and the geographic distribution of those providers. RESULTS: We found abiraterone prescriptions increased from 71,423 in 2013 to a peak of 100,371 in 2015 and enzalutamide prescriptions continued to increase from 29,572 in 2013 to 100,980 in 2016. Prescriptions by urologists increased between 2013 and 2016 while prescriptions by other specialties plateaued. The number of moderate-high prescribing urologists increased from 98 (abiraterone) and 22 (enzalutamide) in 2013, to 301 (abiraterone) and 671 (enzalutamide) by 2016 with 1063 unique urologists prescribing moderate-high volumes of either drug between 2013 and 2016. Among urologists who prescribe androgen deprivation therapy, 5% were moderate-high prescribers of abiraterone and 12% of enzalutamide in 2016. The majority of moderate-high prescribing urologists were in single-specialty groups (70%). CONCLUSION: Urologists are increasingly prescribing oral therapies for metastatic castration-resistant prostate cancer. Understanding the distribution of urologists specializing in castration-resistant prostate cancer therapeutics will help guide future interventions to optimize the care for this important patient population.
Authors: Matthew R Smith; Fred Saad; Simon Chowdhury; Stéphane Oudard; Boris A Hadaschik; Julie N Graff; David Olmos; Paul N Mainwaring; Ji Youl Lee; Hiroji Uemura; Angela Lopez-Gitlitz; Géralyn C Trudel; Byron M Espina; Youyi Shu; Youn C Park; Wayne R Rackoff; Margaret K Yu; Eric J Small Journal: N Engl J Med Date: 2018-02-08 Impact factor: 91.245
Authors: Maha Hussain; Karim Fizazi; Fred Saad; Per Rathenborg; Neal Shore; Ubirajara Ferreira; Petro Ivashchenko; Eren Demirhan; Katharina Modelska; Andrew Krivoshik; Cora N Sternberg Journal: N Engl J Med Date: 2018-06-28 Impact factor: 91.245
Authors: Megan E V Caram; Tudor Borza; Hye-Sung Min; Jennifer J Griggs; David C Miller; Brent K Hollenbeck; Bhramar Mukherjee; Ted A Skolarus Journal: J Oncol Pract Date: 2017-06-19 Impact factor: 3.840
Authors: Nicholas D James; Johann S de Bono; Melissa R Spears; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Alastair W S Ritchie; Claire L Amos; Clare Gilson; Rob J Jones; David Matheson; Robin Millman; Gerhardt Attard; Simon Chowdhury; William R Cross; Silke Gillessen; Christopher C Parker; J Martin Russell; Dominik R Berthold; Chris Brawley; Fawzi Adab; San Aung; Alison J Birtle; Jo Bowen; Susannah Brock; Prabir Chakraborti; Catherine Ferguson; Joanna Gale; Emma Gray; Mohan Hingorani; Peter J Hoskin; Jason F Lester; Zafar I Malik; Fiona McKinna; Neil McPhail; Julian Money-Kyrle; Joe O'Sullivan; Omi Parikh; Andrew Protheroe; Angus Robinson; Narayanan N Srihari; Carys Thomas; John Wagstaff; James Wylie; Anjali Zarkar; Mahesh K B Parmar; Matthew R Sydes Journal: N Engl J Med Date: 2017-06-03 Impact factor: 91.245
Authors: Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf Journal: N Engl J Med Date: 2012-12-10 Impact factor: 91.245
Authors: Pasithorn A Suwanabol; Ari C Reichstein; Z Tuba Suzer-Gurtekin; Jane Forman; Maria J Silveira; Lona Mody; Arden M Morris Journal: J Palliat Med Date: 2018-03-13 Impact factor: 2.947
Authors: Angelina Y Jeong; Eric B Schwartz; Andrea R Roman; Rachel L McDevitt; Mary K Oerline; Elyssa Henry; Christine M Veenstra; Megan E V Caram Journal: JCO Oncol Pract Date: 2021-09-07
Authors: Lillian Y Lai; Samuel R Kaufman; Mary K Oerline; Megan E V Caram; Avinash Maganty; Brent K Hollenbeck; Vahakn B Shahinian Journal: JNCI Cancer Spectr Date: 2022-03-02
Authors: Megan E V Caram; Mary K Oerline; Stacie Dusetzina; Lindsey A Herrel; Parth K Modi; Samuel R Kaufman; Ted A Skolarus; Brent K Hollenbeck; Vahakn Shahinian Journal: Cancer Date: 2020-09-14 Impact factor: 6.860
Authors: Brent K Hollenbeck; Mary Oerline; Samuel R Kaufman; Megan E V Caram; Stacie B Dusetzina; Andy M Ryan; Vahakn B Shahinian Journal: Urology Date: 2020-10-16 Impact factor: 2.649
Authors: Aman Opneja; Gino Cioffi; Asrar Alahmadi; Nelroy Jones; Tin-Yun Tang; Nirav Patil; David L Bajor; Joel N Saltzman; Amr Mohamed; Eva Selfridge; Ankit Mangla; Jill Barnholtz-Sloan; Richard T Lee Journal: Cancer Med Date: 2021-05-31 Impact factor: 4.711
Authors: Rana R McKay; Jason M Hafron; Christine Ferro; Helen M Wilfehrt; Kate Fitch; Scott C Flanders; Michael D Fabrizio; Michael T Schweizer Journal: Adv Ther Date: 2020-10-07 Impact factor: 3.845